Scholarlink

<p>Bispecific antibodies (BsAbs) and multispecific antibodies (MsAbs) represent a transformative class of immunotherapeutics in oncology. These engineered molecules possess the unique ability to simultaneously target two or more distinct antigens, thereby facilitating precise immune cell engagement and disrupting multiple signaling pathways. This comprehensive review focuses on their pivotal role in redirecting both innate (natural killer cells, phagocytes) and adaptive (T cells) immunity, with a particular emphasis on their application against hematologic cancers. Significant clinical successes, exemplified by the FDA approval of agents such as blinatumomab, underscore the profound impact these therapies have had on patient outcomes. Despite their promise, inherent challenges persist, including managing treatment-related toxicities, overcoming tumor resistance mechanisms, and optimizing pharmacokinetic profiles. Ongoing research, however, continues to drive innovative strategies to address these hurdles, highlighting the immense potential of immune engagers to deliver more personalized, scalable, and highly effective cancer treatments in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月27日

查看全文
  • Mustafa T. Ardah,
  • Waleed K. Abdulsahib,
  • Ihsan Khudhair Jasim,
  • H. Malathi,
  • Pradeepta Sekhar Patro,
  • D. Alex Anand,
  • Gunjan Mukherjee,
  • Aashna Sinha,
  • Shakhrijakhon Aminqulov

摘要

Bispecific antibodies (BsAbs) and multispecific antibodies (MsAbs) represent a transformative class of immunotherapeutics in oncology. These engineered molecules possess the unique ability to simultaneously target two or more distinct antigens, thereby facilitating precise immune cell engagement and disrupting multiple signaling pathways. This comprehensive review focuses on their pivotal role in redirecting both innate (natural killer cells, phagocytes) and adaptive (T cells) immunity, with a particular emphasis on their application against hematologic cancers. Significant clinical successes, exemplified by the FDA approval of agents such as blinatumomab, underscore the profound impact these therapies have had on patient outcomes. Despite their promise, inherent challenges persist, including managing treatment-related toxicities, overcoming tumor resistance mechanisms, and optimizing pharmacokinetic profiles. Ongoing research, however, continues to drive innovative strategies to address these hurdles, highlighting the immense potential of immune engagers to deliver more personalized, scalable, and highly effective cancer treatments in the future.